Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2017 - 2025)
Historic Total Non-Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $44.8 million.
- Aclaris Therapeutics' Total Non-Current Liabilities rose 613.36% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 613.36%. This contributed to the annual value of $56.1 million for FY2024, which is 6479.46% up from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Total Non-Current Liabilities is $44.8 million, which was up 613.36% from $46.9 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Total Non-Current Liabilities ranged from a high of $56.1 million in Q4 2024 and a low of $18.0 million during Q2 2024
- Its 5-year average for Total Non-Current Liabilities is $30.1 million, with a median of $25.5 million in 2021.
- Per our database at Business Quant, Aclaris Therapeutics' Total Non-Current Liabilities tumbled by 3631.74% in 2022 and then soared by 15989.25% in 2025.
- Aclaris Therapeutics' Total Non-Current Liabilities (Quarter) stood at $25.5 million in 2021, then dropped by 6.26% to $23.9 million in 2022, then surged by 42.52% to $34.0 million in 2023, then skyrocketed by 64.79% to $56.1 million in 2024, then fell by 20.04% to $44.8 million in 2025.
- Its Total Non-Current Liabilities stands at $44.8 million for Q3 2025, versus $46.9 million for Q2 2025 and $45.0 million for Q1 2025.